Evidence map›Paper›PMID 37880609›Full record

GuidelineBMC nephrology2023

UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE.

Alistair J Roddick, Alexa Wonnacott, David Webb, Angela Watt, Michael A Watson, Natalie Staplin, Alex Riding, Eirini Lioudaki, Apexa Kuverji, Mohsen El Kossi and 8 more

Registry-linked trialOpen access · goldAbstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in BMC nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06982079 (Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease), which is not on this map. Cited by 61 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 6 pooled it
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06982079 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

TypeinterventionalSponsorAin Shams UniversityRan2025 to 2026Enrolled60ConditionsChronic Kidney Disease Stage 5, CKD Stage 4ArmsDapagliflozin 10 mg
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 6 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. [Mesothelial impairment induced by peritoneal dialysis and its potential protective strategies].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026
    Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 1 country.

Alistair J RoddickThe Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, UK.
Alexa WonnacottWales Kidney Research Unit, Cardiff University, Cardiff, UK.
David WebbDiabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK.
Angela WattUKKA Patient Representative, Bristol, UK.
Michael A WatsonUKKA Patient Representative, Bristol, UK.
Natalie StaplinThe Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, UK.
Alex RidingRoyal Free London NHS Foundation Trust, London, UK.
Eirini LioudakiKings College Hospital NHS Trust, London, UK.
Apexa KuverjiJohn Walls Renal Unit, Glenfield Hospital, Leicester, UK.
Mohsen El KossiDoncaster Royal Infirmary, Doncaster, UK.
Patrick HolmesPrimary Care Diabetes Society, Darlington, UK.
Matt HollowayEast Kent Hospitals University NHS Foundation Trust, Canterbury, UK.
Donald FraserWales Kidney Research Unit, Cardiff University, Cardiff, UK.
Chris CarvalhoNorth East London Integrated Care Board, London, UK.
James O BurtonDepartment of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Sunil BhandariHull University Teaching Hospitals NHS Trust and Hull York Medical School, Hull, UK.
William G Herrington *The Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, UK.
Andrew H Frankel *Imperial College Healthcare NHS Trust, London, UK. a.frankel@imperial.ac.uk.
Cardiff University · GBOxford University Hospitals NHS Trust · GBUniversity of Leicester · GBDoncaster Royal Infirmary · GBEast Kent Hospitals University NHS Foundation Trust · GBGlenfield Hospital · GBHull York Medical School · GBImperial College Healthcare NHS Trust · GBKing's College Hospital · GBMedical Research Council · GBPrimary Care Diabetes Society · GBQueen Mary University of London · GBRoyal Free London NHS Foundation Trust · GB

Funding

Medical Research Council MC_UU_00017/3Medical Research Council MR/R007764/1
6 · The paper itself

Abstract

Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full "lay" summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals.

Indexed as

Diabetes Mellitus, Type 2Kidney DiseasesSodium-Glucose Transporter 2 InhibitorsAdultBlood GlucoseHumansHypoglycemic AgentsKidneyUnited KingdomBlood GlucoseHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsAcute kidney injuryChronic kidney diseaseGliflozinGuideline

Identifiers

PMID37880609
PMCPMC10598949
OpenAlexW4387948789

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.